Delayed Fluorodeoxyglucose Positron Emission Tomography Imaging in the Differentiation of Tumor Recurrence and Radiation Necrosis in Pediatric Central Nervous System Tumors: Case Report and Review of the Literature
Open Access
- 26 September 2018
- journal article
- review article
- Published by Cureus, Inc. in Cureus
- Vol. 10 (9) , e3364
Abstract
Malignant central nervous system (CNS) tumors are often treated with radiation therapy, after which clinical and radiographic sequelae can lead to difficulties differentiating tumor recurrence from treatment effect. Magnetic resonance imaging (MRI) is often unable to distinguish between these two entities. The improved ability to delineate concerning foci could lead to earlier tumor detection with quicker access to new therapies and/or clinical trials; conversely, it could alleviate patient concerns in the case of radiation necrosis as the etiology. The utility of positron emission tomography with computed tomography (PET/CT) imaging with fluorodeoxyglucose (FDG) has been explored in CNS tumors in the past, as this imaging modality is widely used in oncologic practices. As there are concerns with false positive imaging in the case of cells with a high metabolic uptake due to causes other than malignancy (i.e. infection, inflammation), delayed FDG PET imaging has been proposed as a mechanism to reduce this confusion. Delayed FDG PET imaging has been explored in several adult and pediatric malignancies, including adult CNS tumors, though there are no current publications applying its use in pediatric CNS tumors. We present two cases of pediatric CNS tumors, where delayed FDG PET imaging helped in the early diagnosis of a recurrence through a distinguishing tumor from the treatment effect.Keywords
This publication has 18 references indexed in Scilit:
- Dual–time point 18 F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and LimitationsSeminars in Nuclear Medicine, 2017
- Comparison between MR Perfusion and 18F-FDG PET in Differentiating Tumor Recurrence from Nonneoplastic Contrast-enhancing Tissue2017
- Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuationOncotarget, 2016
- The Sum of Tumour-to-Brain Ratios Improves the Accuracy of Diagnosing Gliomas Using 18F-FET PETPLOS ONE, 2015
- Dual–Time-Point FDG PET/CT for the Evaluation of Pediatric TumorsAmerican Journal of Roentgenology, 2013
- Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosisJournal of Neuro-Oncology, 2010
- The Efficacy of Dual Time Point F-18 FDG PET Imaging for Grading of Brain TumorsClinical Nuclear Medicine, 2010
- Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesionsAnnals of Nuclear Medicine, 2009
- Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.2008
- 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.2004